Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells

Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells

Aberrant transcription in cancer cells involves the silencing of tumor suppressor genes (TSGs) and activation of oncogenes. Transcriptomic changes are associated with epigenomic alterations such as DNA-hypermethylation, histone deacetylation, and chromatin condensation in promoter regions of silence...

Full description

Bibliographic Details
Main Authors: Somnath Pandey, Rahinatou Djibo, Anaïs Darracq, Gennaro Calendo, Hanghang Zhang, Ryan A. Henry, Andrew J. Andrews, Stephen B. Baylin, Jozef Madzo, Rafael Najmanovich, Jean-Pierre J. Issa, Noël J.-M. Raynal
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Cancers
Subjects:
CDKs
CDK9 inhibitor
toyocamycin
drug screening
epigenetics
cancer
Online Access:https://www.mdpi.com/2072-6694/14/14/3340

Internet

https://www.mdpi.com/2072-6694/14/14/3340

Similar Items